Results 231 to 240 of about 108,172,160 (276)
Some of the next articles are maybe not open access.
Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992We have shown that the urokinase (UK) kringle domain contains a high-affinity plasminogen activator inhibitor-1 (PAI-1) binding site, responsible for the 10-fold faster complex formation between UK and PAI-1 than between PAI-1 and low-molecular-weight urokinase (LMWUK).
J, Mimuro +4 more
openaire +2 more sources
Plasminogen Activators and Plasminogen Activator Inhibitor 1 in Urinary Tract Cancer
Urologia Internationalis, 2010The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic ...
H, Bashar +8 more
openaire +2 more sources
Plasminogen activator inhibitor-1 and the kidney
American Journal of Physiology-Renal Physiology, 2002Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that was isolated 20 years ago. First recognized as an inhibitor of intravascular fibrinolysis, it is now evident that PAI-1 is a multifunctional protein with actions that may be dependent on or independent of its protease inhibitory effects.
openaire +2 more sources
Plasminogen Activator Inhibitor-1
2008Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman +2 more
openaire +1 more source
Plasminogen activator inhibitor‐1 and diabetic nephropathy
Nephrology, 2005SUMMARY: Diabetic nephropathy is characterized by excessive accumulation of extracellular matrix (ECM) in the kidney. Decreased ECM degradation as well as increased ECM synthesis plays an important role in ECM remodeling that favours tissue fibrosis. Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation and PAI‐1 ...
Hi Bahl, Lee, Hunjoo, Ha
openaire +2 more sources
Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets, 2007Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited.
Randal J, Westrick, Daniel T, Eitzman
openaire +2 more sources
Development of Inhibitors of Plasminogen Activator Inhibitor-1
2011Plasminogen activator inhibitor-1 (PAI-1) belongs to the serine protease inhibitor super family (serpin) and is the primary inhibitor of both the tissue-type (tPA) and urokinase-type (uPA) plasminogen activators. PAI-1 has been implicated in a wide range of pathological processes where it may play a direct role in a variety of diseases.
Shih-Hon, Li, Daniel A, Lawrence
openaire +2 more sources
Plasminogen activator inhibitor 1 in thrombotic disease
Current Opinion in Hematology, 1996Impaired fibrinolytic function, mainly due to an elevation of plasma plasminogen activator inhibitor 1 concentration, is a common finding in patients with thrombotic disease. In patients subjected to hip surgery, preoperatively increased levels of plasminogen activator inhibitor 1 seem to be predictive of postoperative deep venous thrombosis.
openaire +2 more sources
A model of the active form of plasminogen-activator-inhibitor-1
Fibrinolysis, 1994A model of the reactive form of plasminogen activator inhibitor-1 (PAI-1) has been constructed using molecular graphics and starting from the known crystal structure of latent PAI-1. The residues P16 to P10', of which P16-P4 form strand 4 of the beta-sheet A (s4A) and P3-P10' form an extended loop in the latent form, have been removed and remodeled ...
K, Aertgeerts +3 more
openaire +2 more sources
Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1
Seminars in Thrombosis and Hemostasis, 2008Important biochemical constituents of the fibrinolytic system include tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). In the current review, we aim to describe the genetic architecture of t-PA and PAI-1. Several genetic polymorphisms in the T-PA and PAI-1 gene have been found to be associated with t-PA and PAI-1 ...
Asselbergs, Folkert W. +5 more
openaire +3 more sources